Given the prevalence of PI3K/AKT/mTOR pathway alterations in patients with breast cancer [17-19] and the availability of several inhibitors of this pathway, this coexistence of molecular alterations may be an important biomarker. This evidence concerns the gene MTOR and breast carcinoma.